Please login to the form below

Not currently logged in

Ex-Pfizer research head Dr David Roblin joins Destiny Pharma

The former head of research at Pfizer's European operations will be medical director at Destiny

Anti-microbial drug development company Destiny Pharma has appointed ex-Pfizer research head Dr David Roblin as medical director.

He headed up Pfizer's European research operations in Sandwich, Kent until March 2011 when he left following the company's announcement it would close the UK research site with the loss of 2,400 jobs.

Dr Roblin said: “After leaving Pfizer I wanted to work with smaller companies where I believe there is a good chance to bring important new medicines to patients and value to investors.

“I was attracted to the science coming out of Destiny. It is creating a class of antibiotics unique in its rapid activity and its efficacy on resistant organisms that are causing many problems in medical practice. This is a step change in antimicrobials and one I am very exciting about contributing to.”

He brings to Destiny 15 years' experience in senior R&D roles at Pfizer and Bayer and five years' experience of medical practice.

Dr Roblin will be joined at Destiny by Sir Nigel Rudd, the former head of BAA and ex-chief of Boots.

Based at the Sussex Innovation Centre near Brighton in the UK, Destiny focuses on anti-microbial drug development and its lead product, XF-73, targets antibiotic resistant strains of Staphylococcus aureus like MRSA.

7th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....